This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Results From HUM, KORS, FOXA
by Zacks Equity Research
Earnings Results From HUM, KORS, FOXA
Relief Rally Post-Midterms, Plus Earnings: HUM, KORS & More
by Mark Vickery
Market indexes are back in the green this morning, following a tight battle between Republicans and Democrats for control of Capitol Hill.
Humana's (HUM) Q3 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Humana Inc.'s (HUM) Q3 earnings gain from Medicare Advantage enrollment, operational efficiency and lower impatient medical utilization
Humana (HUM) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 6.76% and 1.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Trinseo (TSE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Weakness across automotive and tire markets, slowdown in China and higher raw materials costs are likely to impact Trinseo's (TSE) results in Q3.
Is a Surprise Coming for Humana (HUM) This Earnings Season?
by Zacks Equity Research
Humana (HUM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat in Store for Humana (HUM) Stock in Q3 Earnings?
by Zacks Equity Research
Humana's (HUM) Q3 is likely to gain from solid segmental performances and higher enrollment.
Integra (IART) Q3 Earnings Meet Estimates, Revenue View Dips
by Zacks Equity Research
Integra LifeSciences' (IART) success with its channel expansion policy and Codman acquisition raise optimism on the stock.
Tenet Healthcare (THC) Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Tenet Healthcare's (THC) third quarter earnings is likely to gain from solid performance by the Conifer Segment
Will New Products Drive TransEnterix's (TRXC) Q3 Earnings?
by Zacks Equity Research
Among the recent developments, in the third quarter, TransEnterixs (TRXC) gains an FDA approval for its additional 5 millimeter Senhance System instruments.
NuVasive (NUVA) Q3 Earnings Lag Estimates, Revenues Top Mark
by Zacks Equity Research
NuVasive (NUVA) registers balanced growth across its couple of business wings.
Humana (HUM) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemed (CHE) Beats on Q3 Earnings, Raises 2018 Guidance
by Zacks Equity Research
The expansion in adjusted operating margin at Chemed (CHE) raises investor hopes on the stock.
Will CVS Health's (CVS) PBM Strength Boost Q3 Earnings?
by Zacks Equity Research
Despite a challenging pricing scenario, CVS Health (CVS) is currently gaining on high level of service and execution as well as a competitive pricing along with unique integrated model.
Community Health's (CYH) Q3 Loss Widens, Admissions Drop
by Zacks Equity Research
Community Health (CYH) suffers from loss from drop in admissions.
What's in the Offing for Aetna (AET) This Earnings Season?
by Zacks Equity Research
Aetna's (AET) third-quarter earnings to gain from higher revenues, partly offset by increase in expenses.
Molina Healthcare's (MOH) Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Molina Healthcare (MOH) is likely to perform well in the third quarter on the back of a solid Medicaid business and its operational excellence.
Will Obalon's (OBLN) Q3 Earnings Reflect Growth in U.S.?
by Zacks Equity Research
Obalon (OBLN) is expected to register robust U.S. revenues in Q3, backed by higher reorders from existing accounts and new order bookings.
Will Expenses Hurt WellCare Health's (WCG) Q3 Earnings?
by Zacks Equity Research
WellCare Health's (WCG) Q3 bottom line might suffer due to escalating expenses.
What's in the Cards for HCA Healthcare (HCA) in Q3 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) Q3 results are likely to be aided by strong revenues, driven by higher admissions.
Fitbit (FIT) to Gain From Portfolio Strength in Q3 Earnings
by Zacks Equity Research
Fitbit's (FIT) third-quarter results are likely to be driven by growing demand for smartwatches and expanding product portfolio.
Anthem (ANTM) Q3 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Anthem (ANTM) is likely to continue with its winning streak in the third quarter, backed by its Government Business as well as Commercial & Specialty Business segments.
The Zacks Analyst Blog Highlights: Molina, WellCare, Humana and UnitedHealth
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Molina, WellCare, Humana and UnitedHealth
Obamacare Set to Gain From Mid-Term Polls: 4 HMO Picks
by Swarup Gupta
HMOs, which have expanded their market share in the post-Obamacare era, are expected to gain from this trend.
Molina Healthcare (MOH) Divests Arm to Streamline Business
by Zacks Equity Research
Molina Healthcare (MOH) sells its subsidiary Pathways Health and Community Support, LLC to focus on core business and continue with its plan for margin recovery sustainability.